BACKGROUND: Current guidelines recommend both percutaneous catheter ablation (CA) and surgical ablation in the treatment of atrial fibrillation, with different levels of evidence. No direct comparison has been made between minimally invasive thoracoscopic pulmonary vein isolation with left atrial appendage ligation (surgical MIPI) versus percutaneous CA comprising of pulmonary vein isolation as primary treatment of atrial fibrillation. We, therefore, conducted a randomized controlled trial comparing the safety and efficacy of these 2 treatment modalities.
P
ercutaneous electrical isolation of the pulmonary veins (PVs) by catheter ablation (CA) is an effective treatment modality for atrial fibrillation (AF) and is indicated in drug-refractory paroxysmal and persistent AF. [1] [2] [3] [4] However, AF recurrence after PV isolation (PVI) is common. Electrical reconnection of the PVs is considered the most important mechanism for AF recurrence. The surgical Cox-Maze-III procedure is recognized as an effective treatment of AF, but because of its invasiveness and complexity, it is not widely used as a stand-alone procedure nowadays. As an alternative, minimally invasive thoracoscopic PVI (MIPI) was introduced in 1999 by Wolf et al, 5 which allows an epicardial approach for PVI on a beating heart through less invasive incisions. According to the European Society of Cardiology guidelines for AF management, surgical AF ablation should be considered for either patients who failed CA in the past (class IIa, level B) or as a treatment option for patients with symptomatic drug-refractory persistent AF (class IIa, level C). 2 Previous studies including a systematic review found better efficacy of surgical ablation (SA) as compared with CA for AF, although much heterogeneity was present between groups and procedures. Furthermore, a significant proportion of patients undergoing surgical AF ablation has a history of CA. 6 The aim of the present study, therefore, was to perform a randomized controlled trial to compare the efficacy and safety of CA and MIPI as primary ablative treatment of AF. Patients with drug-refractory paroxysmal or early persistent AF were randomized to either percutaneous CA with the objective of PVI without additional lesion sets or surgical MIPI ablation in a 1:1 ratio. All patients were implanted an implantable loop recorder (ILR) to detect atrial arrhythmia recurrence and burden.
METHODS

Purpose
The purpose of this prospective randomized clinical study was to compare the success rate of surgical and percutaneous AF ablation in patients without structural heart disease. Furthermore, we assessed the safety of both invasive treatment strategies. The study was approved by the internal review board and registered (URL: https://www. clinicaltrials.gov; unique identifier: NCT00703157). The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Population
Patients in the Isala Heart Centre (Zwolle, the Netherlands) with symptomatic paroxysmal or early persistent AF (continuous AF duration, <3 months) with failure of at least 1 class 1 or 3 antiarrhythmic drugs (AADs) were eligible. Patients had to be aged ≥18 years. At least 1 symptomatic episode of AF was required within 6 months before inclusion. Structural heart disease, like coronary ischemia, cardiomyopathy or more than mild valvular heart disease, had been excluded by appropriate tests. Patients were excluded when they had permanent or persistent AF >3 months, ejection fraction <40%, left atrial size >50 mm (parasternal long axis), use of amiodarone (no use within 6 months before study entry), history of cerebrovascular disease, pregnancy, life expectancy of <1 year, and previous left atrial ablation.
Enrollment
After written informed consent had been obtained, consecutive patients were implanted a continuous looprecorder (Reveal XT; Medtronic). This ILR is a single-lead electrocardiographic subcutaneous monitoring device able to monitor atrial tachyarrhythmia burden. Patients were followed for a minimum of 1 week after ILR implantation and a maximum of 6 months to establish the required AF burden.
If a patient had demonstrated a minimum of 10% AF burden after 1 week ILR monitoring and had complaints associated with AF, this patient was randomized to one of the treatment arms. Because many patients were highly symptomatic also with a burden <10% or did not reach 10% burden because of early electrical cardioversion, we observed that many patients could not be randomized. A protocol amendment was initiated, therefore, after approval in October 2012, allowing an AF burden of 2% in 1 week as a threshold for randomization. Moreover, patients were followed for a maximum of 2 months instead of 6 months to establish the required AF burden before randomization. The majority (75 of 80) of patients were included in the study before the amendment was effectuated. Patients were randomized electronically at a 1:1 ratio to CA or SA.
Ablation Techniques
Catheter Ablation
The ablation procedure was performed under general anesthesia. Vitamin K antagonists were discontinued for 3 to 5 days before ablation and in selected cases bridged with low-molecular-weight heparin in accordance with local guidelines. Transesophageal echocardiography was performed directly preablation procedure to assess interatrial septum and to exclude left atrial thrombus or other significant structural heart disease. Venous access was obtained through the femoral vein. A 6F deflectable quadripolar
WHAT IS KNOWN?
• Previous studies have suggested a higher efficacy with surgical ablation compared with catheter ablation for atrial fibrillation.
• According to guidelines, surgical ablation should be considered for previous failed catheter ablation.
WHAT THE STUDY ADDS?
• In terms of efficacy, catheter ablation was noninferior to surgical ablation for treatment of paroxysmal and early persistent atrial fibrillation.
• Catheter ablation was associated with fewer complications compared with surgical ablation.
catheter (Bard, Lowell, MA) was positioned in the coronary sinus. Transseptal access to the left atrium (LA) was achieved guided by fluoroscopy and pressure with a Brockenbrough needle, transseptal sheath (SL1, St. Jude), and a guidewire. An initial bolus of 10.000 units of heparin was given and additional administration to achieve an activated clotting time between 300 and 350 seconds. All sheaths were continuously flushed with saline containing 2500 IU heparin per 500 mL saline. PV angiography was performed for ipsilateral PV ostia to provide a geometric reference for catheter navigation and localization of the antrum. A 3-dimensional electroanatomic map of the LA was constructed (CARTO, Biosense Webster). Isolation of all PVs was performed using circumferential periostial applications of radiofrequency energy, with a power limit of 40 W on the anterior LA and 30 W on the posterior LA, and verified with a decapolar circular mapping catheter (Lasso, Biosense Webster). The ablation was performed with a 3.5-mm irrigated tip catheter (Thermocool, Biosense Webster). Radiofrequency energy was applied for 20 to 60 seconds until the local electrogram amplitude was eliminated. The end point of the ablation procedure was defined as the absence or dissociation of PV potentials documented with a circular decapolar mapping catheter within the PVs ≥30 minutes post-ablation.
Surgical Ablation
MIPI and left atrial appendage ligation was performed by a highly experienced cardiothoracic surgeon who performed >1000 radiofrequency maze procedures. The MIPI procedure was performed under general anesthesia. In supine position, a double-lumen tracheal tube was introduced. In the right hemithorax, a 5-to 10-cm incision in the fourth intercostal space in the anterior axillary line was placed. A soft tissue retractor was used to introduce the scope through the sixth intercostal space (submammary). The pericardium was opened anterior to the phrenic nerve. Two stay sutures were placed in the pericardium. Blunt dissection of Waterstone groove was performed followed by a blunt dissection and opening of the oblique sinus caudal of the right inferior PV. Then, blunt dissection and opening of the oblique sinus cranial of the right superior PV between right superior PV and right pulmonary artery was performed. Hereafter a silastic tape was placed around the right sided PVs to facilitate proper positioning of the device. An irrigated bipolar clamp device (Cardioblate; Medtronic) was introduced for PVI. This device has a self-regulating ablation protocol based on an impedance feedback system. Transmurality feedback is indicated based on a steady-state plateau in tissue impedance. After introduction of the device, antral tissue around the right-sided PVs was clamped after gentle traction of the tape, and radiofrequency energy was applied to ablate the left atrial wall adjacent to the junction with the right-sided PVs. After radiofrequency energy application, the clamp was repositioned approaching the antrum of the PV pair from 180°, and then a second radiofrequency application was performed. Isolation of the PVs was confirmed with pacing maneuvers at the LA-PV junction. After 30 minutes of pacing, maneuvers were repeated to check for electrical reconnection. The left hemithorax was opened similar to the right hemithorax, except for the incision of the pericardium, that was incised posterior to the phrenic nerve.
Additional left atrial appendage ablation or removal or exclusion with stapler or preferably with endoloop was performed. The left atrial appendage exclusion was verified on transesophageal echocardiography. Ganglionated plexi ablation and additional ablation lines were not performed.
End Points
The primary end point was defined as freedom from atrial tachyarrhythmias with a duration of ≥30 seconds during follow-up, without the use of antiarrhythmic drugs. A 3-month blanking period was initiated. Secondary end points were AF burden <0.5% and reduction of absolute AF burden during follow-up. AF burden post-ablation was calculated per month. The absolute decrease in average AF burden post-ablation was determined as compared with the average AF burden ≤6 months before the procedure. The safety end point was the absence of procedure-related complications. Complications were regarded as major if they resulted in death, irreversible damage to structures or organs, stroke, atrioesophageal fistula, conversion to sternotomy, or need for reoperation. Pericardial effusion not needing intervention and managed conservatively, small groin hematoma not requiring blood transfusion and without significant drop in hemoglobin, and procedure-related mild infection (such as urinary tract infection or respiratory tract infection) were regarded as minor complications.
Postprocedural Care
Anticoagulation was reinitiated as soon as possible, after control of bleeding, and was continued at least 3 months after the ablation procedure. When CHADS2 score was ≥1, patients were kept on anticoagulation. During the blanking period of 3 months, the AADs were tapered off.
Follow-Up
During follow up, patients were seen at 3 months followed by outpatient clinic visits every 6 months after the ablation procedure or at other occasions when patients had symptoms. At each visit, a 12-channel ECG and ILR device download was performed to assess any recurrence of arrhythmias.
Statistical Analysis
All statistical analyses were performed using the Statistical Package for the Social Sciences, version 24 (IBM Nederland B.V., Amsterdam, the Netherlands). A 2-sided P value of <0.05 was considered significant. To assess the primary efficacy end point, we performed both intention-to-treat analysis and as-treated patient analysis because of the small sample size. As-treated analysis was performed to assess the safety end point. Categorical variables were reported as frequencies and percentages with 95% CI where appropriate. Quantitative/ continuous variables were described using the mean and SD when normally distributed or using the median with the interquartile range when not normally distributed. To determine whether the data were normally distributed, the Shapiro-Wilk and Kolmogorov-Smirnov tests were used in combination with Q-Q plots and histograms. Data were not normally distributed, and, therefore, t test could not be used. The Mann-Whitney U test was used for the continuous variables. The χ 2 test or Fisher exact test was used for the comparison of categorical variables. We performed Cox survival analysis for efficacy of both treatment strategies. The proportional hazards assumption was graphically and statistically verified. Time to first documented recurrence was analyzed by the log-rank statistic and plotted using Kaplan-Meier survival curve. We assessed the proportion of patients with AF burden <0.5 during follow-up with a χ 2 test for differences between the 2 treatment arms. We additionally tested for differences in absolute AF burden reduction.
RESULTS
Patient Characteristics
Eighty patients were enrolled in the study and underwent ILR implantation. Twenty-eight patients did not reach randomization criteria. Twenty-seven patients did not reach the required AF burden, and 1 patient was excluded because of an LA size >50 mm. A total of 52 patients were randomized, 26 to CA and 26 to SA. Figure 1 shows the patient distribution. All patients in the catheter group received CA. In the SA group, 23 patients underwent MIPI, and 2 patients received CA because after randomization, these patients refused SA. One patient in the SA group was excluded because of significant coronary artery disease necessitating coronary artery bypass surgery combined with radiofrequency maze. In the CA group, 1 patient was excluded from analyses after ablation because on the preprocedural transthoracic echocardiography and transesophageal echocardiography, a much larger LA was seen than expected (>50 mm anteroposterior diameter, with LA volume >50 mL/m 2 ). Baseline characteristics are demonstrated in Table 1 . Table 2 demonstrates the procedural characteristics. The total median procedure time was not significantly different (P=0.14) between CA (168 minutes; range, 124-195) and MIPI (176 minutes; range, 155-221). In the CA group, complete electrical isolation was achieved in all PVs (100%). In 1 patient with AF which could not be converted to sinus rhythm using electrical cardioversion after PVI, an additional roofline and fractionation guided ablation was performed. Afterward, the patient was converted to sinus rhythm. In the MIPI group, PVI and left atrial appendage ligation was successful in all patients. In 1 patient, the ligament of Marshall was cut in addition to PVI, again because of recurrent AF after electrical cardioversions. This patient could subsequently not be converted to sinus rhythm. Hospitalization duration was significantly longer (P<0.001) in MIPI with a median of 9 days (range, 8-10) versus a median of 3 days (range, 2-3) after CA.
Procedural Characteristics
Efficacy of Catheter Versus Surgical AF Ablation
In intention-to-treat analysis of the primary end point CA, single-procedure arrhythmia-free survival without the use of AAD after 2 years of follow-up was noninferior to SA (2-year Kaplan-Meier event rate estimates, 56.0% and 29.2%, respectively; log-rank P=0.059; hazard ratio [HR], 0.56; 95% CI, 0.26-1.20), as shown in Figures 2  and 3 . There was no significant interaction of age with arrhythmia-free survival (HR, 0.98; 95% CI, 0.94-1.02; P=0.28). In the as-treated population, difference in single-procedure arrhythmia-free survival between CA and MIPI was statistically significant (2-year Kaplan-Meier event rate estimates, 55.6% and 27.3%, respectively; log-rank P=0.048; HR, 0.55; 95% CI, 0.26-1.16). Univariate and multivariate Cox regression analysis results are described in Table I in the Data Supplement.
Similar results for CA and MIPI were seen after 1-year follow-up in intention-to-treat analysis (1-year KaplanMeier event rate estimates, 56.0% and 33.3%, respectively; log-rank P=0.103; HR, 0.60; 95% CI, 0.28-1.30) and as-treated analysis (1-year Kaplan-Meier event rate estimates, 55.6% and 31.8%, respectively; log-rank P=0.09; HR, 0.59; 95% CI, 0.28-1.27).
The decrease in AF burden, 2 years after ablation, was 24.4% (interquartile range, 11.0%-61.5%) in CA compared with 14.1% (interquartile range, 10.4%-47.3%) in MIPI (P=0.76). In as-treated patient analysis, a significantly greater proportion of patients had an AF burden <0.5% after CA compared with MIPI (60.0% versus 27.3%; P=0.047), in intentionto-treat analysis, the difference did not reach statistical significance (P=0.058). Table II in the Data Supplement demonstrates the AF burden during the 2 years of follow-up.
Safety
Procedure-related adverse events during follow-up occurred significantly more often in MIPI than in CA (37.5% versus 11.1%; difference, 26.4%; 95% CI, 3.2%-49.6%; P=0.046). This was mainly because of a difference in major complications (20.8% in MIPI versus 0% in CA; difference, 20.8%; 95% CI, 4.8%-36.9%; P=0.029). Table 3 shows procedural and nonprocedural adverse events. All complications in the CA group were minor complications, whereas in the MIPI group, there were 5 major complications. In the MIPI group, 1 patient required an acute conversion to median sternotomy because of bleeding from a laceration of the left upper PV at the LA junction. One patient required pericardiocentesis for pericardial effusion with tamponade. Another patient in the MIPI group developed postoperative lung herniation through one of the rightsided surgical incisions for which reconstruction with a patch of marlex mesh was performed. One MIPI procedure was complicated by left phrenic nerve paralysis, and another patient developed a unilateral recurrent laryngeal nerve paralysis related to endotracheal intubation. One patient in the CA developed a ventilatorassociated pneumonia, treated with antibiotics. One patient in the CA group developed a urosepsis because of an indwelling urinary catheter. Pericarditis without significant effusion was successfully treated with ibuprofen in both groups. 
DISCUSSION Main Findings
This is the first randomized controlled trial that randomized patients with symptomatic drug-refractory paroxysmal or early persistent AF to surgical or percutaneous ablation as a first invasive procedure. The follow-up strategy of this study comprised continuous rhythm monitoring with the use of an ILR in all patients.
The main finding of this study is that PVI with percutaneous CA was noninferior to surgical MIPI in terms of arrhythmia-free survival after 2 years of follow-up. However, in the as-treated analysis, CA resulted in less atrial tachyarrhythmia recurrences, as compared with MIPI. Both ablation strategies reduced AF burden significantly. However, 2 years after ablation, a significant greater proportion of patients in the CA group had a low AF burden (<0.5%) compared with surgical MIPI. When assessing AF burden <0.5% in our study, which is only 0.8 hours per week, success rates would be 60% for CA and 27.3% for MIPI (P=0.047). Atrial arrhythmia-free outcome of CA in this study is in line with the results of a recent randomized study on percutaneous CA of AF.
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Of note, our findings are in contrast with results of earlier randomized trials comparing SA and CA. 7, 8 In these trials, however, a large proportion of patients with unsuccessful previous CA were included, resulting in importantly different study populations.
Head-to-head randomized comparison of primary SA versus CA has not been performed before. Previous randomized studies comparing SA and CA of AF always included patients with unsuccessful previous CA. The FAST trial (Atrial Fibrillation Catheter Ablation Versus Surgical Ablation Treatment) was a prospective randomized trial in 124 patients who had failed a previous CA procedure or had hypertension and an enlarged LA. 7 In this latter study, patients were randomized in a 1:1 ratio to either CA or MIPI. Importantly, two-third of the patient population had unsuccessful CA before randomization. In addition, cardiac rhythm follow-up method in the FAST trial did not consist of continuous monitoring with ILR. Therefore, shorter or asymptomatic episodes of AF can be easily missed in this way. The 12-month success rate, defined as freedom from atrial tachyarrhythmias >30 seconds in duration, measured by 7-day Holter monitoring, was significantly higher for the SA group compared with the CA group (65.6% versus 36.5%; P=0.0022). Similar efficacy results were seen in a trial by Pokushalov et al. 8 They randomized 64 patients with paroxysmal and persistent AF after a failed initial transcatheter endocardial PV ablation to repeat CA (n=32) or SA (n=32). 8 The follow-up method consisted of continuous monitoring with an ILR. The surgical procedure consisted of PVI, lines to create a posterior box lesion, and ablation of ganglionic plexi. At 12 months of follow-up, 81% of SA patients were free of atrial arrhythmias without AAD versus 47% in the CA group (P=0.004). The relatively poor efficacy in the catheter group was attributed to the fact that patients included in these studies were in an advanced stage of AF and might have required additional substrate ablation. Aging and associated disease promote development of elastic fibers, collagen, increase in fat content, and smooth muscle cell hyperplasia. This process results in an AF substrate that has a hindering effect on radiofrequency electrical current in penetrating the tissue and limits creation of transmural lesions. In vivo and in vitro studies demonstrated a large heterogeneity in thickness and composition of the atrial epicardium and myocardium. 9 Traditionally, surgical epicardial approach is performed in patients with ≥1 failed endocardial ablation attempts. In these patients, it is more likely to create electrical PV disconnection with additional epicardial ablation than in patients without previous endocardial ablation(s). Therefore, performing surgical epicardial AF ablation after previous endocardial ablations increases the probability of creating durable transmural lesions without gaps and thus elimination of PV and non-PV triggers and effective modification of AF substrate.
In European and American guidelines, both surgical and percutaneous approach are recommended as first ablation treatment modality, although with different class and level of evidence (class 1, A class 2a, A for CA in paroxysmal and persistent AF and class 2b, B for SA). 10, 11 CA is a commonly applied first-line treatment of symptomatic drug refractory paroxysmal and persistent AF, whereas surgical epicardial ablation is mostly performed in patients with previously failed CA procedures or evidence of advanced AF substrate. 12, 13 Minimally invasive surgery for AF showed a 12-month AADfree success rate of 65% to 92% in different review studies. 14, 15 Based on the current evidence, especially regarding the safety aspect, we would recommend not to perform first-line stand-alone SA of paroxysmal and early persistent AF. The future guideline committee should, therefore, consider a class III (level of evidence B) recommendation for primary stand-alone SA of paroxysmal AF.
Safety
In the present study, CA had a better safety profile than SA (MIPI). Procedure-related complications occurred significantly more often in MIPI than in CA, which is largely explained by occurrence of major complications (20.8% in MIPI versus 0% in CA; P=0.029). This finding is in line with findings of the FAST trial, in which major early complication rate was significantly higher for the SA group compared with CA (23.0% versus 3.2%). 7 Pokushalov et al 8 also reported a much higher major complication rate after surgical procedures compared with CA (22% versus 3.2%; P=0.02). SA and CA of AF are highly complex procedures. The most recent worldwide survey of CA reported a 4.5% complication rate. 16 It has to be recognized that the data were from voluntary surveys and likely underestimate the true complication rates. In our present study, most complications were general surgery-related complications, like bleeding and damage to organs or the nervous system. The high complication rate with surgical AF ablation was observed in many studies involving highly experienced surgeons, possible highlighting the need for cardiac electrophysiological surgery as a subspecialty to reduce complication rates.
Cardiac Rhythm Monitoring
The present study is the first to randomize patients to MIPI or CA only in patients undergoing a first invasive treatment for AF with continuous rhythm monitoring with ILR to assess outcome. It has been shown that monitoring of symptoms in patients with AF is unreliable. Only 52% of symptoms correlate with documented measures of AF, and nearly half of AF episodes are asymptomatic. 17 The Heart Rhythm Society task force recommend 24-hour Holter monitoring as an acceptable monitoring strategy for patients enrolled in a clinical trial. Hanke et al 18 demonstrated that intermittent monitoring dramatically overestimates the success rate of ablation procedures. Another study in 647 AF patients with a mean AF burden of 0.12% showed that even with intensive intermittent monitoring, at least 30 days of Holter monitoring would be required to reach a sensitivity of 82% in detection of AF. 19 For scientific and for AF patient management decisions, continuous monitoring after ablation procedures is strongly recommended.
Limitations
The main limitation of our study is the small sample size. Therefore, results of this trial should be interpreted as a pilot study. Absolute numbers in efficacy are similar in intention-to-treat and as-treated analyses, although even low crossover rates resulted in no significant differences in efficacy in the first and a significant difference in the latter. A larger than expected proportion of patients did not meet the requirement of AF burden >10%, which was originally set as inclusion criterion. Highly symptomatic episodes of AF required electrical cardioversion before patients could reach the required 10% burden within 1 week of loop recorder monitoring. Later, we changed this inclusion criterion to 2% AF burden. We did not systematically perform an electrophysiological study in patients with recurrent AF after MIPI. The current study shows a relatively high rate of postoperative recurrent atrial arrhythmias. However, AF burden data obtained with an ILR demonstrates that the mean AF burden was significantly reduced after surgery. The results of a previous study demonstrated that symptomatic atrial arrhythmias after minimally invasive epicardial PVI were predominantly because of reconnection of epicardial ablation lines. 20 Possibly, additional epicardial surgical radiofrequency applications or more extensive testing for PVI could have resulted in better outcome. Third, this trial was conducted in a single center. Pooling of randomized data from different centers and new, larger multicenter randomized studies are mandatory.
Conclusions
In patients with paroxysmal and early persistent AF without structural heart disease, percutaneous CA was noninferior to minimally invasive SA in long-term follow-up. However, CA was considerably safer than SA.
